Trial Profile
Xydalba Utilization Registry: A Multicenter, Prospective and Retrospective Registry to Characterize the Use of Xydalba
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 21 Jul 2020
Price :
$35
*
At a glance
- Drugs Dalbavancin (Primary)
- Indications Bacterial infections; Gram-positive infections; Skin and soft tissue infections
- Focus Therapeutic Use
- Sponsors Correvio
- 15 Jul 2020 Status changed from recruiting to discontinued.
- 12 Dec 2019 Status changed from not yet recruiting to recruiting.
- 12 Oct 2018 New trial record